Ming-Song Wu

机构：Beihai People's Hospital · ORCID：0000-0001-8513-0637

发表论文 9 篇 · 总被引 58 次 · h-index 4

代表论文

• Multicenter, retrospective GUIDANCE001 study comparing transarterial chemoembolization with or without tyrosine kinase and immune checkpoint inhibitors as conversion therapy to treat unresectable hepatocellular carcinoma: Survival benefit in intermediate or advanced, but not early, stages (2025 · Hepatology · 被引 27)
• Prognostic value of radiological and pathological complete response following immune-based conversion therapy in patients with unresectable hepatocellular carcinoma (GUIDANCE004) (2025 · JHEP Reports · 被引 7)
• Association of CK19 expression with the efficacy of adjuvant transarterial chemoembolization after hepatic resection in hepatocellular carcinoma patients at high risk of recurrence. (2022 · PubMed · 被引 7)
• Survival benefit of hepatectomy after complete or partial response to conversion therapy in unresectable hepatocellular carcinoma (GUIDANCE003): a multi-center study (2025 · Liver Cancer · 被引 6)
• Erratum: Multicenter, retrospective GUIDANCE001 study comparing transarterial chemoembolization with or without tyrosine kinase and immune checkpoint inhibitors as conversion therapy to treat unresectable hepatocellular carcinoma: Survival benefit in intermediate or advanced, but not early, stages (2025 · Hepatology · 被引 4)
• Prognostic Usefulness of Clinical Complete Response after PD-1 Inhibitor-Based Combination Therapy for Unresectable Hepatocellular Carcinoma (GUIDANCE006) (2025 · Liver Cancer · 被引 3)